Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698769 | 0.83 | BCHE (0.54) | TLR9MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL14901162 | 0.83 | TLR9 (0.49) | TLR9NPC1RAB9ASMN1; SMN2PDGFRB | |
| SCHEMBL3809859 | 0.79 | TLR9 (0.53) | TLR9NPC1RAB9ASMN1; SMN2PDGFRB | |
| SCHEMBL3638905 | 0.77 | PLAU (0.40) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL31663159 | 0.77 | PLAU (0.40) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL15884313 | 0.75 | FGFR3 (0.56) | KDRFLT3MAPK1PIK3CAMAPK8 | |
| SCHEMBL5759348 | 0.74 | MAPK1 (0.53) | TLR9RAB9APDGFRBKDRMAPK1 | |
| SCHEMBL13083328 | 0.74 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2MAPK1PIK3CA | |
| SCHEMBL19480349 | 0.74 | KDM4E (0.47) | NPC1RAB9ASMN1; SMN2MAPK1PIK3CA | |
| SCHEMBL9375675 | 0.74 | ASIC3 (0.59) | NPC1RAB9ASMN1; SMN2ASIC3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | CLAUS ECKHARD (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-8217042-B2 | Pyridopyrazines and their use as modulators of kinases | ZENTARIS GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| US-8193186-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2012-06-05 | — | — | US | disclosed |
| EP-1636228-B1 | NOVEL PYRIDOPYRAZINES AND USE THEREOF AS KINASE MODULATORS | AETERNA ZENTARIS GMBH (DE) | 2008-10-22 | — | — | EP | disclosed |
| EP-1957487-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | AEterna Zentaris GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20080113991-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | ZENTARIS GMBH (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7323468-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2008-01-29 | — | — | US | disclosed |
| US-20070275972-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-11-29 | — | — | US | disclosed |
| US-7276507-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007054556-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ÆTERNA ZENTARIS GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1785423-A1 | Pyridopyrazine derivatives and their use as kinase modulators | Zentaris GmbH (DE) | 2007-05-16 | — | — | EP | disclosed |
| EP-1636228-A1 | NOVEL PYRIDOPYRAZINES AND USE THEREOF AS KINASE MODULATORS | Zentaris GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1628976-A1 | NOVEL PYRIDOPYRAZINES AND USE THEREOF AS KINASE INHIBITORS | Zentaris GmbH (DE) | 2006-03-01 | — | — | EP | disclosed |
| US-20050032803-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | ZENTARIS GMBH (DE) | 2005-02-10 | — | — | US | disclosed |
| US-20040266777-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
| WO-2004104003-A1 | NOVEL PYRIDOPYRAZINES AND USE THEREOF AS KINASE MODULATORS | ZENTARIS GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004104002-A1 | NOVEL PYRIDOPYRAZINES AND USE THEREOF AS KINASE INHIBITORS | ZENTARIS GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275972-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | MKI67, MAP4K2, MAP3K5 | TLR9 4705/4885NPC1 4435/4885RAB9A 4105/4885 |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | TLR9 4654/4885NPC1 4680/4885RAB9A 3378/4885 |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | TLR9 4654/4885NPC1 4680/4885RAB9A 3378/4885 |
| US-20040266777-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | PDXK, MKI67, MAP4K2 | TLR9 4309/4885NPC1 4575/4885RAB9A 4423/4885 |
| US-20050032803-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | MKI67, MAP4K2, MAP3K5 | TLR9 4705/4885NPC1 4435/4885RAB9A 4105/4885 |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | TLR9 4654/4885NPC1 4680/4885RAB9A 3378/4885 |
| US-20080113991-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | MKI67, MAP4K2, MAP3K5 | TLR9 4705/4885NPC1 4435/4885RAB9A 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.